Shetty Nishit, Shephard Meredith J, Rockey Nicole C, Macenczak Hollie, Traenkner Jessica, Danzy Shamika, Vargas-Maldonado Nahara, Arts Peter J, Le Sage Valerie, Anderson Evan J, Lyon G Marshall, Fitts Eric Charles, Gulick Dalia A, Mehta Aneesh K, El-Chami Mikhael F, Kraft Colleen S, Wigginton Krista R, Lowen Anice C, Marr Linsey C, Rouphael Nadine G, Lakdawala Seema S
Department of Civil and Environmental Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Department of Civil, Environmental, and Architectural Engineering, University of Kansas, Lawrence, Kansas, USA.
J Virol. 2024 Dec 17;98(12):e0161224. doi: 10.1128/jvi.01612-24. Epub 2024 Nov 26.
Establishing effective mitigation strategies to reduce the spread of influenza virus requires an improved understanding of the mechanisms of transmission. We evaluated the use of a controlled human infection model using an H3N2 seasonal influenza virus to study critical aspects of transmission, including symptom progression and the dynamics of virus shedding. Eight volunteers were challenged with influenza A/Perth/16/2009 (H3N2) virus between July and September 2022 at Emory University Hospital. Viral shedding in the nasopharynx, saliva, stool, urine, and respiratory aerosols was monitored over the quarantine period, and symptoms were tracked until day 15. In addition, environmental swabs were collected from participant rooms to examine fomite contamination, and participant sera were collected to assess seroconversion by hemagglutination inhibition or microneutralization assays. Among the eight participants, influenza virus infection was confirmed in six (75%). Infectious virus or viral RNA was found in multiple physiological compartments, fecal samples, aerosol particles, and on surfaces in the immediate environment. Illness was moderate, with upper respiratory symptoms dominating. In participants with the highest viral loads, antibody titers rose by day 15 post-inoculation, while in participants with low or undetectable viral loads, there was little or no increase in functional antibody titers. These data demonstrate the safety and utility of the human infection model to study features critical to influenza virus transmission dynamics in a controlled manner and will inform the design of future challenge studies focused on modeling and limiting transmission.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05332899.
We use a controlled human infection model to assess respiratory and aerosol shedding kinetics to expand our knowledge of influenza infection dynamics and help inform future studies aimed at understanding human-to-human transmission.
建立有效的缓解策略以减少流感病毒传播需要更好地理解传播机制。我们评估了使用H3N2季节性流感病毒的可控人类感染模型来研究传播的关键方面,包括症状进展和病毒脱落动态。2022年7月至9月期间,8名志愿者在埃默里大学医院接受了甲型/珀斯/16/2009(H3N2)病毒的挑战。在隔离期监测鼻咽部、唾液、粪便、尿液和呼吸气溶胶中的病毒脱落情况,并追踪症状直至第15天。此外,从参与者房间收集环境拭子以检查污染物表面污染情况,并收集参与者血清通过血凝抑制或微量中和试验评估血清转化。在8名参与者中,6人(75%)被确诊感染流感病毒。在多个生理腔室、粪便样本、气溶胶颗粒以及直接环境的表面发现了传染性病毒或病毒RNA。病情为中度,以上呼吸道症状为主。在病毒载量最高的参与者中,接种后第15天抗体滴度上升,而在病毒载量低或检测不到的参与者中,功能性抗体滴度几乎没有增加或没有增加。这些数据证明了人类感染模型在以可控方式研究对流感病毒传播动态至关重要的特征方面的安全性和实用性,并将为未来专注于建模和限制传播的挑战研究设计提供信息。
临床试验
本研究已在ClinicalTrials.gov注册,注册号为NCT05332899。
我们使用可控人类感染模型来评估呼吸道和气溶胶脱落动力学,以扩展我们对流感感染动态的认识,并有助于为未来旨在理解人际传播的研究提供信息。